AA
CARM

Ancora Advisors’s Carisma Therapeutics CARM Stock Holding History

Ancora Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-65
Closed -$148 – 1849
2024
Q1 		$148 Hold
65
– – ﹤0.01% 1749
2023
Q4 		$190 Hold
65
– – ﹤0.01% 1656
2023
Q3 		$275 Hold
65
– – ﹤0.01% 1674
2023
Q2 		$570 Hold
65
– – ﹤0.01% 1618
2023
Q1 		$201 Hold
65
– – ﹤0.01% 1840
2022
Q4 		$1K Hold
65
– – ﹤0.01% 1662
2022
Q3 		$1K Hold
65
– – ﹤0.01% 1888
2022
Q2 		$1K Hold
65
– – ﹤0.01% 2063
2022
Q1 		$1K Hold
65
– – ﹤0.01% 2239
2021
Q4 		$1K Hold
65
– – ﹤0.01% 2275
2021
Q3 		$1K Hold
65
– – ﹤0.01% 2117
2021
Q2 		$6K Hold
65
– – ﹤0.01% 1648
2021
Q1 		$3K Buy
+65
New +$3.07K ﹤0.01% 1596

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ancora Advisors's CARM Position: Q2 2024 in Review

Ancora Advisors sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 65 shares — an estimated $148 sold.

Ancora Advisors first reported a position in CARM in Q1 2021 and held it in 13 quarters. The position peaked at $6K in Q2 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Ancora Advisors reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ancora Advisors sold 65 Carisma Therapeutics shares in Q2 2024, an estimated $148.
  • Ancora Advisors first reported a position in Carisma Therapeutics in Q1 2021 and held it in 13 quarters.
  • Ancora Advisors's Carisma Therapeutics position peaked at $6K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Ancora Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.